We were delighted to speak with Professor Jeremy Adler (Michigan Medicine, University of Michigan, Ann Arbor, MI, USA) around his talk around the findings from the validation study of the Simplified Endoscopic Mucosal Assessment of Crohn’s Disease (SEMA-CD).
The abstract entitled ‘VALIDATION OF THE SIMPLIFIED ENDOSCOPIC MUCOSAL ASSESSMENT OF CROHN’S DISEASE (SEMA-CD) A NOVEL ENDPOINT TO ASSESS ENDOSCOPIC IMPROVEMENT WITH REAL WORLD DATA’ was presented at the virtual 2022 Crohn’s & Colitis Congress, 20-22 January, 2022.
- Why is there a need for an endoscopic mucosal assessment in clinical practice? (0:23)
- Could you tell us a little about the Simplified Endoscopic Mucosal Assessment of CD (SEMA-CD)? (1:24)
- What were the aims and design of your validation study? (2:08)
- What were the findings of the study? (2:48)
- What are the implications of these findings for clinical practice and future clinical trial design? (5:22)
Disclosures: Jeremy Adler discloses consulting for Janssen Research & Development, LLC; and receiving grant/ research support from Janssen Research & Development, LLC.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual Crohn’s & Colitis Congress 2022.
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!